AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03977844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning
Description: CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles \[48, 64\]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
Study NCT03977844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Resources (CR)
Description: The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
Study NCT03977844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Resources (CR)
Description: The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
Study NCT04066192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
Study NCT04066192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A medically inert placebo medication will be used as described in the study arms.
Study NCT04708626 — intervention group
Intervention type: OTHER
Intervention: Description and analysis
Description: Collection of clinical, laboratory and radiological data from medical records.
Study NCT04708626 — intervention group
Intervention type: OTHER
Intervention: Description and analysis
Description: Collection of laboratory data.
Study NCT03977844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Resources + eBT
Description: The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities \[65\]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app.
Study NCT02973659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
Study NCT00876109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
Study NCT02973659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Study NCT00786916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Study NCT00786916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Study NCT00786916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Study NCT04840095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketones
Description: Sports supplement that is administered mid-scan.
Study NCT04840095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement is administered mid-scan.
Study NCT03813303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Administration of midazolam by anesthesiologist for sedation.
Study NCT03515889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ideal Protein Weight Loss Method
Description: An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute).
Study NCT03515889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Loss
Description: This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute).
Study NCT03813303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Administration of fentanyl by anesthesiologist for sedation.
Study NCT03813303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Administration of propofol by anesthesiologist for sedation.
Study NCT02621905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sporanox
Description: At least 2 capsules twice a day for 3 weeks
Study NCT02621905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lozanoc
Description: At least 2 capsules twice a day for 3 weeks
Study NCT02174094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Study NCT02174094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00530023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiniMed Paradigm REAL-Time System
Description: MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
Study NCT04468048 — intervention group
Intervention type: OTHER
Intervention: Music: Nada Himalaya performed by S. G. Sachchidananda
Description: Music: Nada Himalaya performed by S. G. Sachchidananda
Study NCT04574362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: One 75mg orally disintegrating tablet
Study NCT04574362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02700646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental recommendations
Study NCT02700646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: standard care
Study NCT02162628 — intervention group
Intervention type: DEVICE
Intervention: Exair Prolapse Repair System
Study NCT02162628 — intervention group
Intervention type: PROCEDURE
Intervention: Total Native Tissue Repair
Study NCT04049994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uro-Vaxom
Description: Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
Study NCT04049994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study NCT03055234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Treprostinil
Description: Extended-release oral tablet for TID administration
Study NCT03055234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for TID administration
Study NCT00963664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
Study NCT00963664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
Study NCT01761617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga class once per week
Description: The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio.
Study NCT01761617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga class twice per week
Description: The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio.
Study NCT02539472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
Study NCT00668369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gradual immunosuppression drug withdrawal.
Description: Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
Study NCT01072318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg
Study NCT04420026 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Interact Active Tracker
Description: Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
Study NCT01194297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: One dose of live attenuated influenza vaccine, according to routine immunization recommendations
Study NCT02704130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transarterial embolization
Description: In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
Study NCT02704130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
Study NCT01194297 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza vaccine
Description: One dose of inactivated influenza vaccine, according to routine immunization recommendations
Study NCT02238301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bold sequence patients test
Description: Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
Study NCT02704130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
Study NCT03030638 — intervention group
Intervention type: DRUG
Intervention: Olodaterol
Description: Drug
Study NCT03030638 — intervention group
Intervention type: DRUG
Intervention: Indacaterol
Description: Drug
Study NCT02215434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Biolipid B2 (blanked/placebo)
Description: the intervention will be the comparison effects of both emulsions
Study NCT02238301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bold + ASL sequence
Description: A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation.
Study NCT02215434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biolipid B2 (blanked/placebo)
Description: the intervention will be the comparison effects of both emulsions
Study NCT02215434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone, Transdermal, Behavior
Description: Transdermal 0.5% testosterone Biolipid/B2
Study NCT02805192 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Size Measurement by a Smart phone App
Study NCT01903278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV
Study NCT01903278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys /RBV
Study NCT00812929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
Study NCT02215434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone, Transdermal, Behavior
Description: Transdermal 0.5% testosterone Biolipid/B2
Study NCT00812929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915
Description: This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
Study NCT02287142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachial plexus nerve block
Description: All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
Study NCT01544374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracking & Feedback
Description: Systems based intervention tracking oncology consultations and feeding back information to surgeons
Study NCT03558607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months.
Study NCT01502800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 761
Description: ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
Study NCT01502800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 761 Weekly Administration
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study NCT01502800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bi-Weekly Administration of ARQ 761
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study NCT02773979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
Study NCT02773979 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
Study NCT02773979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02813031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional meat products
Study NCT01502800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two Consecutive Weeks Administration of ARQ 761 with one week of rest
Description: If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2.
Study NCT02813031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional meat products
Study NCT04823338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conectar Jugando Online Program
Description: Online play sessions with modern board and card games guided by the study researchers